No Data
East Asia Pharmaceutical: East Asia Pharmaceutical Third Quarter Report 2024
East Asia Pharmaceutical Third Quarter Report 2024
Zhejiang East-Asia Pharmaceutical (605177.SH): The net income for the first three quarters was 45.1692 million yuan, a decrease of 47.21% year-on-year.
Gelonghui October 30th | Zhejiang East-Asia Pharmaceutical (605177.SH) announced that in the first three quarters of 2024, revenue decreased by 4.13% to 0.963 billion yuan; net income attributable to the shareholders of the listed company decreased by 47.21% to 45.1692 million yuan, with basic earnings per share of 0.40 yuan.
Zhejiang East-Asia Pharmaceutical (605177.SH): Intends to appoint Chizhengming as a global strategy and development consultant.
Gelonghui October 11th | Zhejiang East-Asia Pharmaceutical (605177.SH) announced that, according to the company's global strategy development, industrial layout needs, the company plans to appoint Mr. Chi Zhengming as a strategic and development consultant. He will provide consulting services for the company's overall development goals, development strategies, operational strategies, etc., and sign a 'Strategic and Development Consultant Agreement' with Mr. Chi Zhengming for a term of three years, from October 11, 2024 to October 10, 2027. The annual remuneration for strategic and development consultants is 1.3 million yuan (including tax). Mr. Chi Zhengming is a shareholder of the company's controlling shareholder, actual controller, holding more than 5% of the company's shares, and
Express News | Zhejiang East-Asia Pharmaceutical and others established a pharmaceutical research company.
East Asia Pharmaceutical 2024 Semi-Annual Report
No Data
No Data